| Product Unit Size | Cost | Quantity | Stock |
|---|
GLYX-13 is a peptide with the sequence T-P-P-T that exhibits antidepressant and neuromodulatory activities; it acts as a partial agonist at NMDA receptors. GLYX-13 reverses PCP- and ketamine-induced memory deficits and increases sensitivity to long-term potentiation (LTP). GLYX-13 also decreases depressive symptoms in vivo without psychomimetic or dissociative effects.
| Cas No. | 117928-94-6 |
|---|---|
| Purity | ≥98% |
| Formula | C18H31N5O6 |
| Formula Wt. | 413.48 |
| Chemical Name | L-Threonyl-L-prolyl-L-prolyl-L-threoninamide |
| IUPAC Name | L-Threonyl-L-prolyl-L-prolyl-L-threoninamide |
| Synonym | Rapastinel |
| Solubility | Soluble in water (2 mg/mL), DMSO (30 mg/mL). |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Rajagopal L, Burgdorf JS, Moskal JR, et al. GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice. Behav Brain Res. 2015 Nov 26. [Epub ahead of print]. PMID: 26632337.
Burgdorf J, Zhang XL, Weiss C, et al. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience. 2015 Nov 12;308:202-11. PMID: 26343295.
Burgdorf J, Kroes RA, Zhang XL, et al. Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats. Behav Brain Res. 2015 Nov 1;294:177-85. PMID: 26210936.
Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry. 2015 Oct 1;172(10):950-66. PMID: 26423481.
